Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain

Nature Medicine

Volumn 3, Issue 6, 1997, Pages 632-638

  Selivanova, Galina ^a   Iotsova, Violetta ^b,d   Okan, Ismail ^a   Fritsche, Michael ^c   Ström, Marika ^a   Groner, Bernd ^c   Grafström, Roland C ^b   Wiman, Klas G ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c TUMOR BIOLOGY CENTER   (Germany)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; SYNTHETIC PEPTIDE;

APOPTOSIS; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER INHIBITION; CANCER THERAPY; CARBOXY TERMINAL SEQUENCE; DNA BINDING; ETIOLOGY; GROWTH INHIBITION; HUMAN; HUMAN CELL; POINT MUTATION; PRIORITY JOURNAL; REPRESSOR GENE; TRANSACTIVATION; TRANSCRIPTION INITIATION;

APOPTOSIS; CELL DIVISION; DOXYCYCLINE; FLUORESCENT ANTIBODY TECHNIQUE; HELA CELLS; HUMANS; OSTEOSARCOMA; PEPTIDES; RECOMBINANT FUSION PROTEINS; TRANS-ACTIVATION (GENETICS); TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030961889     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0697-632     Document Type: Article

References (23)

1. Greenblatt, M.S., Bennet, W.P., Hollstein, M. & Harris, C.C. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res. 54, 4855-4878 (1994).
2. Malkin D. et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasias. Science 250, 1233-1238 (1990).
3. Donehower, LA. et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 356, 215-221 (1992).
4. Baker, S.J., Markowitz, E.R., Fearon, J.K., Willson, K.V. & Vogelstein, B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Sciencs 249, 912-915 (1990).
5. Yonish-Rouach, E. et al. Wild type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature 353, 345-347 (1991).
6. Kern, S.E. et al. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256, 827-832 (1992).
7. Cho, Y., Gorina, S., Jeffrey, P.D. & Pavletich, N.P. Crystal structure of a p53 tumor-suppressor-DNA complex: Understanding tumorigenic mutations. Science 265, 356-355 (1994).
8. Hupp, T.R. & Lane, D.P. Allosteric activation of latent p53 tetramers. Curr. Biol. 4, 865-875 (1994).
9. Hupp, T.R., Sparks, A. & Lane, D.P. Small peptides activate the latent sequence-specific binding function of p53. Cell 83, 237-245(1995).
10. Hupp, T.R., Meek, D.W., Midgley, C.A. & Lane, D.P. Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Res. 21, 3167-3174 (1993).
11. Halazonetis, T.D. & Kandil, A.N. Conformational shift propagate from oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO J. 12, 5057-5064(1993).
12. Niewolik, D., Vojtesek, B. & Kovarik, J. p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence. Oncogens 10, 881-890(1995).
13. Abarzua, P. et al. Restoration of the transcription activation function to mutant p53 in human cancer cells. Oncogens 13, 2477-2482 (1996).
14. Abarzua, P., LoSardo, J.E., Gubler, M.L. & Neri, A. Microinjecton of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53. Cancer. Res. 55, 3490-3494 (1995).
15. Selivanova, G. et al. The single stranded DNA end binding site of p53 coincides with the C-terminal regulatory region. Nucleic Acids Res. 24, 3560-3567 (1996).
16. Brugidou, J., Legrand, C., Mery, J. & Rabie, A. The retro-inverso form of a homeobox-derived short peptide is rapidly internalized by cultured neurones: A new basis for an efficient intracellular delivery system. Biochem. Biophys. Res. Commun. 214, 685-693 (1995).
17. Lowe, S.W. et al. p53 status and the efficacy of cancer therapy in vivo. Science 266, 807-810 (1994).
18. Wieczorek, A.M., Waterman, J.L.F., Waterman, M.J.F. & Halazonetis, T.D. Structure-based rescue of common tumor-derived p53 mutants. Nature Med. 2, 1143-1146 (1996).
19. Symonds, H. et al. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78, 703-711 (1994).
20. Iotsova, V. & Stephelin, D. Antisense p53 provokes changes in HeLa cell growth and morphology. Eur. J. Cell Biol. 68, 122-132 (1995).
21. Gossen, M. & Bujard, H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA 89, 5547-5551 (1992).
22. Ramqvist, T. et al. Wild type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53. Oncogens 8, 1495-1500 (1993).
23. Okan, I. et al. The EBV-encoded LMP1 protein inhibits p53-triggered apoptosis but not growth arrest. Oncogens 11, 1027-1031 (1995).